FDA Approves Octapharma’s Octagam® 10% for Adult Dermatomyositis

The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% the first and only intravenous immunoglobulin (IVIg) to be indicated for the treatment of adult dermatomyositis! The U.S. Food and Drug Administration (FDA) has granted approval to Octapharma USA for Octagam® 10% [Immune Globulin Intravenous (Human)], the first and only intravenous…

Continue Reading

New mouse model for sIBM

The Myositis Association (TMA) is excited to announce the groundbreaking development of the first humanized mouse model for sporadic inclusion body myositis (sIBM) achieved through TMA’s innovative Pilot Research Funding Program.  With the generous funding of The Myositis Association’s Pilot Research Grant, Dr. Thomas Lloyd, a member of TMA’s Medical Advisory Board, and his research…

Continue Reading